EC
PRCT icon

EntryPoint Capital’s Procept Biorobotics PRCT Stock Holding History

EntryPoint Capital’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,780
Closed -$218K – 836
2025
Q2 		$218K Sell
3,780
-145
-4% -$8.2K 0.11% 445
2025
Q1 		$229K Sell
3,925
-1,348
-26% -$92K 0.1% 473
2024
Q4 		$425K Sell
5,273
-577
-10% -$49.3K 0.18% 177
2024
Q3 		$469K Buy
+5,850
New +$416K 0.27% 70
2024
Q2 		– Sell
-844
Closed -$41.7K – 1467
2024
Q1 		$41.7K Buy
844
+38
+5% +$1.81K 0.04% 848
2023
Q4 		$33.8K Buy
+806
New +$27.4K 0.03% 884

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

EntryPoint Capital's PRCT Position: Q3 2025 in Review

EntryPoint Capital sold out of Procept Biorobotics (PRCT) in Q3 2025, closing a stake of 3,780 shares — an estimated $218K sold.

EntryPoint Capital first reported a position in PRCT in Q4 2023 and held it in 6 quarters. The position peaked at $469K in Q3 2024. 242 funds tracked by Wall St. Rank hold PRCT as of Q3 2025.

  • EntryPoint Capital reported no remaining Procept Biorobotics position as of Q3 2025 after selling out during the quarter.
  • EntryPoint Capital sold 3,780 Procept Biorobotics shares in Q3 2025, an estimated $218K.
  • EntryPoint Capital first reported a position in Procept Biorobotics in Q4 2023 and held it in 6 quarters.
  • EntryPoint Capital's Procept Biorobotics position peaked at $469K in Q3 2024.
  • 242 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2025.

Based on EntryPoint Capital's 13F filing for Q3 2025, filed 13 Nov 2025.